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Aims MicroRNAs (miRNA) are important non-coding modulators controlling patterns of gene expression. However,
profiling and validation of circulating miRNA levels related to adverse cardiovascular outcome has not been per-




In a multicentre, prospective ACS cohort, 1002 out of 2168 patients presented with ST-segment elevation myocardial
infarction (STEMI). Sixty-three STEMI patients experienced an adjudicated major cardiovascular event (MACE, defined
as cardiac death or recurrent myocardial infarction) within 1 year of follow-up. From a miRNA profiling in a matched
derivation case–control cohort, 14 miRNAs were selected for validation. Comparing 63 cases vs. 126 controls, 3
miRNAs were significantly differentially abundant. In patients with MACE, miR-26b-5p levels (P= 0.038) were
decreased, whereas miR-320a (P= 0.047) and miR-660-5p (P= 0.01) levels were increased. MiR-26b-5p has been sug-
gested to prevent adverse cardiomyocyte hypertrophy, whereas miR-320a promotes cardiomyocyte death and apopto-
sis, and miR-660-5p has been related to active platelet production. This suggests that miR-26b-5p, miR-320a, and miR-
660-5p may reflect alterations of different pathophysiological pathways involved in clinical outcome after ACS.
Consistently, these three miRNAs reliably discriminated cases from controls [area under the receiver-operating charac-
teristic curve (AUC) in age- and sex-adjusted Cox regression for miR-26b-5p = 0.707, miR-660-5p = 0.683, and miR-
320a =0.672]. Combination of the three miRNAs further increased AUC to 0.718. Importantly, addition of the three
miRNAs to both, the Global Registry of Acute Coronary Events (GRACE) score and a clinical model increased AUC
from 0.679 to 0.720 and 0.722 to 0.732, respectively, with a net reclassification improvement of 0.20 in both cases.
...................................................................................................................................................................................................
Conclusion This is the first study performing profiling and validation of miRNAs that are associated with adverse cardiovascular
outcome in patients with STEMI. MiR-26b-5p, miR-320a, and miR-660-5p discriminated for MACE and increased
risk prediction when added to the GRACE score and a clinical model. These findings suggest that the release of
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specific miRNAs into circulation may reflect the activation of molecular pathways that impact on clinical outcome
after STEMI.
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Introduction
MicroRNAs (miRNAs), a class of non-coding RNAs, are important
post-transcriptional modulators.1 Recently, experimental studies
demonstrated that circulating miRNAs are involved in cell-to-cell
communication. As miRNAs are bound to transport proteins or
encapsulated in microvesicles and exosomes, they are protected
from degradation and can be reliably measured in plasma samples.2,3
Differences in miRNA levels between healthy subjects and patients
with acute coronary syndrome (ACS)4 indicate that miRNAs may
serve as biomarkers predicting outcome beyond the currently used
scores in patients presenting with ACS and unravel molecular path-
ways involved in the disease.
We aimed to assess changes in miRNA levels in ST-segment eleva-
tion myocardial infarction (STEMI) patients that are associated with
cardiovascular outcome. Differential expression levels of miRNAs
may lead to improving our understanding of pathophysiological
mechanisms that are related to clinical outcomes in this patient
population.
Methods
All experimental procedures and computational analyses are described in
detail in Supplementary material online.
Results
The study population included STEMI patients with available EDTA-
plasma sample (n= 1002) derived from a previously described multi-
centre, prospective ACS-cohort (NCT01000701).5
Derivation cohort
To detect whether miRNAs are associated with cardiovascular out-
come in patients presenting with STEMI (Figure 1A), a miRNA profil-
ing was conducted in plasma samples from patients with a major
adverse cardiovascular event (MACE, defined as cardiac death or
recurrent myocardial infarction) and without a MACE within 1-year
follow-up. Patients with confounding variables known to influence
miRNA levels (see Supplementary material online, Table S1) were
excluded. Cases with MACE and controls without MACE were
matched (see Supplementary material online, Table S2) according to
age, gender, symptom onset to balloon angioplasty time, and dual-
antiplatelet therapy. Using a miRNA-profiling approach, 752 miRNAs
were assessed with the miRCURY LNATM Universal RT miRNA
PCR Human panel Iþ II (Exiqon, Vedbaek, Denmark). The 752
miRNAs comprise miRNAs that were—based on array, qPCR, and
published literature data—most consistently expressed. We identi-
fied 92 miRNAs in all samples, with an average of 290 miRNAs
detectable per sample. Differences of miRNA levels between cases
(n= 7) and controls (n= 7) were found for 15 miRNAs (P< 0.05;
Supplementary material online, Table S3). MiRNAs detected in <10
samples (miR-663a, miR-27a-3p, and miR-211-5p) were excluded
from further analysis. Due to their known role in cardiomyocyte
apoptosis and adverse hypertrophy, miR-320a6 and miR-150a7 were
included. Finally, 14 miRNAs were carried over to the validation
phase. Baseline characteristics and medication of the derivation
cohort are shown in Supplementary material online, Tables S4 and S5.
Validation cohort
For validation of differentially abundant miRNAs, we conducted a
case–control study in 1002 STEMI patients from the multicentre,
prospective SPUM-ACS-Cohort. The 14 miRNAs identified in the
screening phase were investigated in 63 cases and 126 matched con-
trols. Patient characteristics and medication are shown in
Supplementary material online, Tables S6 and S7. Cases were older
and presented more frequent with renal failure, whereas controls
had higher cholesterol levels. The other variables, including medica-
tion, showed no significant differences. Of note, the comparison of
baseline characteristics and medication did not reveal significant dif-
ferences between the validation and derivation cohort
(Supplementary material online, Tables S8 and S9). In addition, no sig-
nificant differences were found between storage time of case and
control samples in the derivation (P= 0.235) and validation (P= 0.
815) cohort.
Out of 14 miRNAs, 9 miRNAs were reliably detected in the major-
ity of samples. Of note, UniSp6 that was used as a spike-in control for
cDNA synthesis showed no difference between samples.
Levels of three miRNAs, miR-26b-5p, miR-660-5p, and miR-320a,
differed in cases as compared with controls (all P< 0.05, Welch’s t-
test, Benjamini–Hochberg corrected). Patients experiencing MACE
had lower levels of miR-26b-5p, but higher levels of miR-660-5p and
miR-320a (Figure 1B).
To test the association of miR-26b-5p, miR-660-5p, and miR-
320a with MACE, we calculated the area under the receiver-
operating characteristic curves (AUC) (Figure 1C) of Cox regres-
sion models. MiR-26b-5p (AUC 0.707), miR-660-5p (AUC
0.683), and miR-320a (AUC 0.672) discriminated patients with
MACE from patients without MACE. Importantly, combination of
these three miRNAs yielded an increased AUC of 0.718. Of note,
high-sensitivity troponin T (AUC 0.666) and pro B-type natriu-
retic peptide (pro-BNP) (AUC 0.674) showed lower discrimina-
tory power as compared with the three miRNAs (Figure 1C). We
further assessed whether miR-26b-5p, miR-660-5p, and miR-
320a may add predictive value to a clinical model (hypertension,
diabetes mellitus, smoking, hypercholesterolemia, previous myo-
cardial infarction, and family history of coronary artery disease)
or the Global Registry of Acute Coronary Events (GRACE)-


















..Score (Figure 1D). MiR-26b-5p most profoundly increased AUC,
whereas miR-660-5p and miR-320a showed only a moderate or
no increase in AUC (Figure 1D). Addition of the three miRNAs to
a clinical model or the GRACE score, however, further moder-
ately increased AUC from 0.722 to 0.732 and 0.679 to 0.720,
respectively. Comparing the GRACE score to the miRNA-
extended GRACE score and the clinical model to the miRNA-
extended clinical model directly yielded the highest increase for
miR-26b-5p (NIR for miR-26b-5p-extended GRACE score-
= 0.16; NIR for miR-26b-5p-extended clinical model = 0.11) when
miRNAs were assessed individually and a further moderately
increased net reclassification improvement (NRI) of 0.2 in both
cases when the three miRNAs were combined (Figure 1D). After
integration of renal function (estimated glomerular filtration rate
(eGFR)) in the miRNA-extended clinical model, the NRI
remained significantly increased (NRI of clinical
modelþ eGFRþ (miR-26b-5pþmiR-660-5pþmiR-320a) = 0.17
[95% confidence interval (CI) 0.15–0.19)]. In addition, when the
analysis was limited to cases only used in the validation cohort,
the added prognostic value of the three miRNAs remained signifi-
cant [NRI for clinical modelþ (miR-26b-5pþmiR-320aþmiR-
660-5p) = 0.16 (95% CI, 0.14–0.18); NRI for GRACE




Figure 1 (A) Study design and workflow. Cases are patients who experienced a major cardiovascular event (defined as cardiac death or recurrent
myocardial infarction) within 1 year; controls did not experience a major cardiovascular event within 1 year. (B) Fourteen miRNAs identified in the
miRNA-profiling from the derivation cohort were analysed in the validation phase. In the validation cohort (cases, n= 63; controls, n= 126), miR-
26b-5p, miR-660-5p, and miR-320a were significantly (P < 0.05) differently abundant between cases and controls after Welch’s t-test and Benjamini–
Hochberg correction. Since fold-changes (log2) are calculated for dCt-values, negative fold-changes imply higher miRNA levels in cases as compared
with controls. (C) Area under the receiver-operating characteristic curve values for miRNAs and biomarkers when classifying cases vs. controls in
Cox regression models adjusted for sex and age. MiR-26b-5p (area under the receiver-operating characteristic curve 0.707), miR-660-5p (area under
the receiver-operating characteristic curve 0.683), and miR-320a (area under the receiver-operating characteristic curve 0.672) reliably discriminate
cases from controls. Combination of the three miRNAs enhances discriminatory power to an area under the receiver-operating characteristic curve
of 0.718. (D) Addition of miR-26b-5p, miR-660-5p, and miR-320a increases the predictive value of the Global Registry of Acute Coronary Events
score and a clinical model. Shown are area under the receiver-operating characteristic curve and net reclassification improvement for the clinical
model and the Global Registry of Acute Coronary Events score with and without the three miRNAs. CI, confidence interval; hsTNT, high-sensitivity
troponin T; pro-BNP, pro B-type natriuretic peptide.

























































































This is the first study that performed profiling and validation of
miRNAs that are associated with adverse cardiovascular outcome
using a large multicentre, prospective ACS cohort. We identified
three miRNAs (i.e. miR-26b-5p, miR-660-5p, and miR-320a) that dis-
criminate patients experiencing MACE from those without it within
the first year after STEMI. As these miRNAs have been reported as
modulators of adverse cardiac hypertrophy,8 cardiomyocyte apopto-
sis,6 and active platelet count9 in experimental studies, our findings
shed light onto a miRNA-mediated modulation of molecular path-
ways that may be related to adverse clinical outcomes.
Previous studies focused on selected and mostly cardiac-derived
miRNA panels or examined surrogate outcomes. We conducted an
miRNA profiling of 752 miRNAs in a derivation cohort to identify
miRNAs that are related to adjudicated MACE (defined as cardiac
death or recurrent myocardial infarction). Validation in a matched
case–control design involving 63 patients with MACE identified three
miRNAs (miR-26b-5p, miR-660-5p, and miR-320a) that are differen-
tially abundant between cases and controls. A decreased level of
miR-26b-5p and higher levels of miR-660-5p and miR-320a were
detected in patients experiencing a MACE. Interestingly, experimen-
tal studies suggest that these three miRNAs are involved in pathophy-
siological mechanisms relevant for cardiovascular outcome.
Overexpression of miR-26b-5p reduced cardiac hypertrophy in an
experimental transverse aortic constriction model in vivo.8
Therefore, it is conceivable that lower miR-26b-5p levels in our study
predict MACE. Elevated levels of circulating miR-320a as observed in
patients with MACE in our study have previously been reported in
cardiac tissues derived from end-stage heart failure as compared with
control samples.10,11 Interestingly, overexpression of miR-320
increased cardiomyocyte apoptosis, potentially through the inhibition
of heat-shock protein 20.6 For miR-660, overexpression of miR-660
increased production of active platelets in vitro,9 indicating a potential
role for thrombotic events, as in recurrent myocardial infarction.
These experimental studies suggest that differential expression of
miR-26b-5p, miR-660-5p, and miR-320a are related to pathophysio-
logical mechanisms that trigger heart failure, recurrent myocardial
infarction, and cardiac death. Consistently, miR-26b-5p, miR-660-5p,
and miR-320a were good discriminators of MACE. Combination of
these three miRNAs improved discriminatory power. In predictive
models using the GRACE score and a clinical model, addition of miR-
26b-5p resulted in the highest increase in AUC and NRI, whereas
miR-660-5p and miR-320a did not substantially improve prognostica-
tion when added alone to these models. However, combination of
the three miRNAs moderately increased AUC and NRI as compared
with the miR-26b-5p-extended models, potentially reflecting the
involvement of different pathophysiological pathways relevant for
clinical outcome
Of note, several studies have examined acute miRNA regulation in
patients with STEMI (Supplementary material online, Table S10) in dif-
ferent cell types12 or in plasma samples using restricted panels of
muscle-enriched miRNAs,13,14 or miRNA profiling.12,15,16 However,
these miRNAs detected in diagnostic studies of STEMI were not
associated with MACE in our prognostic study. Notably, studies that
used a profiling and validation approach for the diagnosis of ACS have
shown promising results to establish miRNAs as early diagnostic
biomarkers.4 The present study, however, for the first time has per-
formed a miRNA profiling and validation approach to assess miRNA
related to adverse prognosis in a secondary prevention cohort of
STEMI patients. Furthermore, we show that miRNAs may improve
risk prediction when added to currently used models and scores. In a
different clinical setting, i.e. in a primary prevention cohort analysing
19 candidate miRNAs, Zampetaki et al.17 have observed that three
endothelial cell or platelet-enriched miRNAs (i.e. miR-126, miR-223,
and miR-197) were associated with the incident myocardial infarc-
tion. However, no initial miRNA profiling related to myocardial
infarction and cardiovascular death was performed, and these three
miRNAs were not tested for improvement of net reclassification.
Whether differential abundance of circulating miRNAs is a result
of different release mechanisms or modulated intracellular produc-
tion has to be determined in future studies. Notably, Hergenreider
et al.18 and others have shown that circulating miRNAs exert impor-
tant functions after cellular uptake, indicating that miRNAs continu-
ously modulate pathophysiological pathways depending on their
abundances. Therefore, an miRNA-targeted therapy may evolve as a
strategy to counteract heart failure or thrombotic events and
improve outcome in patients presenting with STEMI. However, to
date, no clinical therapies targeting these miRNAs exist.
In conclusion, using a profiling and validation approach, we identi-
fied miR-26b-5p, miR-660-5p, and miR-320a to be associated with
adverse cardiovascular events in patients presenting with STEMI.
Importantly, in experimental studies, these miRNAs are involved in
pathways regulating cardiomyocyte apoptosis, adverse cardiac
remodelling, and active platelet production. Therefore, these three
miRNAs may reflect pathophysiological mechanisms relevant for clin-
ical outcome and may be further examined for improvement of risk
stratification in patients with STEMI.
Supplementary material
Supplementary material is available at European Heart Journal online.
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